Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS)
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
Women pregnant with twins or triplets are at high risk of preterm birth, yet no intervention
or approach has served to reduce this risk. A recently completed trial by the NICHD sponsored
Maternal Fetal Medicine Units (MFMU) Network has, for the first time, demonstrated a
treatment that substantially reduces the rate of preterm birth in women at high risk for
preterm delivery (i.e. progesterone therapy). Preterm birth was reduced by 35% among
progesterone-treated women with a singleton pregnancy when compared with women receiving
placebo. The current trial compares weekly treatment by injection of progesterone with
placebo in women pregnant with twins or triplets.
Phase:
Phase 3
Details
Lead Sponsor:
The George Washington University Biostatistics Center
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)